STOCK TITAN
  1. Home
  2. Sec-filings
  3. BOLT
  4. [Form 4] Bolt Biotherapeutics, Inc. Insider Trading Activity

BOLT insider reports 23,000 RSUs grant and 125-share purchase

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bolt Biotherapeutics (BOLT) insider activity: the company’s Senior VP, Finance and PAO reported two transactions. On June 6, 2025, the officer purchased 125 shares of common stock at $5.492, acquired under the Employee Stock Purchase Plan. On October 22, 2025, the officer received 23,000 restricted stock units for no consideration; each RSU represents one share upon settlement and will vest in full on September 15, 2026, assuming continued employment. Following these transactions, direct beneficial ownership stands at 23,943 shares.

Positive

  • None.

Negative

  • None.
Insider Nemec Sarah
Role Senior VP, Finance and PAO
Bought 125 shs ($686.50)
Type Security Shares Price Value
Grant/Award Common Stock 23,000 $0.00 --
Purchase Common Stock 125 $5.492 $686.50
Holdings After Transaction: Common Stock — 23,943 shares (Direct)
Footnotes (1)
  1. Shares acquired under the issuer's Employee Stock Purchase Plan and therefore exempt under Rule 16b-3(c) The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nemec Sarah
(Last) (First) (Middle)
900 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Senior VP, Finance and PAO
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/06/2025 P 125(1) A $5.492 943 D
Common Stock 10/22/2025(2) (3) A 23,000 A $0(2) 23,943 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares acquired under the issuer's Employee Stock Purchase Plan and therefore exempt under Rule 16b-3(c)
2. The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
3. The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date.
/s/ William P. Quinn, Attorney-in-Fact 10/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BOLT report on this Form 4?

An officer purchased 125 shares at $5.492 and received 23,000 RSUs for no consideration, with total direct beneficial ownership now 23,943 shares.

How many RSUs were granted to the BOLT officer and what are the terms?

The officer received 23,000 restricted stock units; each RSU equals one common share at settlement and vests in full on September 15, 2026, assuming continued employment.

When and at what price did the BOLT officer buy common stock?

On June 6, 2025, the officer purchased 125 shares at a price of $5.492 per share under the Employee Stock Purchase Plan.

What is the officer’s total direct beneficial ownership after these transactions?

Following the reported transactions, direct beneficial ownership is 23,943 shares.

What is the role of the reporting person at Bolt Biotherapeutics (BOLT)?

The reporting person is an Officer, serving as Senior VP, Finance and PAO.

What is the earliest transaction date reported on the Form 4?

The earliest transaction date noted is October 24, 2025.